TNP-470

TNP-470

An angiogenesis inhibitor used in the treatment of cancer to reduce blood vessel formation in tumors.
References in periodicals archive ?
Her paper, "Angiogenesis Inhibitors Endostatin or TNP-470 Reduce Intimal Neovascularization and Plaque Growth in Apolipoprotein e-Deficient Mice," showed that the growth of the small blood vessel network feeding coronary artery plaques in mice could be reduced by giving them an angiogenesis inhibitor.
Ten received a protein called endostatin, and 15 got a synthetic compound called TNP-470.
However, the mice getting TNP-470 showed a more modest 60 percent increase, while those given endostatin experienced plaque growth of only 28 percent, says study coauthor Karen S.
Beyond limiting nutrients available to plaque's fat and collagen cells, endostatin and TNP-470 may shrink plaque by hampering the activity of roving immune cells called macrophages, Moulton says.
The drug, TNP-470, is designed to prevent the formation of microscopic blood vessels that cancerous tumors need to grow and move throughout the body, said Dr.
Success against breast cancer with the intravenously administered TNP-470, Nguyen said, would hold broad promise for treating other metastatic tumors - those prone to spreading.
Cancerous tumors can spread through the lymphatic system and bloodstream, but Nguyen said studies on animals show that TNP-470 seems to work against both modes of transmission.
Earlier studies of TNP-470 on humans and animals showed that the drug is safe and stops tumors from growing, if it doesn't shrink them, Nguyen said.
In the second study, in which VX-2 tumors in rabbits were injected with the angiogenesis inhibitor, TNP-470, contrast enhanced ultrasound using Imagent allowed visualization of tumor blood flow in response to the anti-angiogenesis treatment.
The NCI also has presented data on the anti-angiogenic activity of PPI-2458 and in vivo efficacy in a variety of xenograft animal models of human cancer, which indicate that the activity of PPI-2458 compares favorably to that of another compound of this class known as TNP-470.
Data presented separately by the NCI on the anti-angiogenic activity of PPI-2458 and its in vivo efficacy in a variety of xenograft animal models of human cancer favorably compared the activity of PPI-2458 to that of another compound in this class known as TNP-470.
This abstract favorably compares the activity of PPI-2458 to that of another compound of this class known as TNP-470.